EGFR and non-small cell lung carcinoma: This study found that cell‐free DNA analysis reveals clinically important information during EGFR‐targeted therapy in non‐small‐cell lung cancer (NSCLC): At baseline, quantitative tumour‐derived cell‐free DNA levels in plasma provided prognostic information and correlated with tumour burden.